Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.


Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals (CSE:AGN) completes manufacturing of DMT and appoints UK stroke experts for phase 2 trials

John Ballem  December 8, 2021

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

GlobeNewswire December 8, 2021

Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial

GlobeNewswire December 2, 2021

Algernon Pharmaceuticals (CSE:AGN) welcomes new CFO

John Ballem  November 30, 2021

Algernon Pharmaceuticals Announces New Chief Financial Officer

GlobeNewswire November 30, 2021

Top 5 Stories of the Week: Zoomd (TSXV:ZOMD), Highmark (TSXV:HMRK), FuelPositive (TSXV:NHHH), Max Resource (TSXV:MXR), and Algernon (CSE:AGN)

Julia Kennedy  November 26, 2021

The Power Play by The Market Herald Releases New Interviews with Algernon Pharmaceuticals, Better Plant Sciences, and Mednow Inc. Discussing Their Latest News

Accesswire November 24, 2021

Algernon Pharmaceuticals (CSE:AGN) receives U.S. FDA support for Phase 1 Ifenprodil small cell lung cancer study

John Ballem  November 24, 2021

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study

GlobeNewswire November 24, 2021

Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation

GlobeNewswire November 23, 2021

Today’s market summary: European lockdowns make waves in global markets

Julia Kennedy  November 19, 2021

The Power Play by The Market Herald Interviews Christopher Moreau of Algernon Pharmaceuticals Discussing Their Latest News

Accesswire November 19, 2021

Algernon (CSE:AGN) announces positive feedback on its planned Phase 1/2a DMT Human Stroke Study

John Ballem  November 19, 2021

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

GlobeNewswire November 19, 2021

CSE Bulletin: Consolidation - Algernon Pharmaceuticals Inc. (AGN)

Newsfile November 18, 2021

Algernon Pharmaceuticals Announces Share Consolidation

GlobeNewswire November 17, 2021

The Power Play by The Market Herald Releases New Interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals Discussing Their Latest News

Accesswire November 1, 2021

Algernon Pharmaceuticals (CSE:AGN) establishes optimum treatment period for DMT in neuron study

John Ballem  November 1, 2021

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

GlobeNewswire November 1, 2021

Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

John Ballem  October 21, 2021